Taiho and Toray end alliance for early-stage overactive bladder therapy
This article was originally published in Scrip
Taiho Pharmaceutical, a subsidiary of Otsuka in Japan, and Toray Industries have decided to end an alliance for the co-development of a therapy for overactive bladder disorders, apparently in consideration of the increasing competition in the sector.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.